Bristol-Myers Squibb Co
Passage of Inflation Reduction Act gives Medicare historic new powers over drug prices
A pharmacist collects medications for prescriptions at a pharmacy. Simon Dawson | Bloomberg | Getty Images Medicare is poised to renegotiate the prices of some of its most expensive drugs through a historic expansion of its power, which could reduce costs for many seniors as well as federal spending on its prescription drug plan. The […]
Read More
Investor Sarat Sethi has some stock picks to play inflation and a consumer slowdown
Investors should stick to companies that can keep generating earnings as they navigate high inflation and a consumer slowdown, according to DCLA’s Sarat Sethi. “Earnings are going to drive this market going forward,” Sethi said Monday on CNBC’s “Squawk Box.” “Not multiple expansion, not liquidity, it’s going to be where do we find earnings, and […]
Read More
Artificial intelligence drug hunters are nearing a pivotal stage in their development
Efforts to use artificial intelligence to discover drugs have been underway for about a decade but industry watchers are predicting an inflection point is nearing for investors, who have been looking for ways to determine how AI-first drug developers should be valued. AI and machine learning offer the potential to speed up the hunt for […]
Read More
Having a woman in the boardroom or C-suite drives even wider diversity, study finds
shironosov | Getty Images If you want to take a good guess at a company’s gender diversity record, you might want to first look at who its CEO or board chair is, according to the findings of a new study. Having a female CEO at the helm of a company or chairing its board tends […]
Read More
Here’s Jim Cramer’s advice to navigate this uncertain earnings season
Earnings season is entering full swing on Wall Street, and CNBC’s Jim Cramer said Monday that investors would be wise to take a wait-and-see approach toward shares of companies that are about to report quarterly numbers. “In this environment, it’s always going to be fragile on the upside and easy on the downside, because the […]
Read More
Signs point to biotech M&A heating up, Wells Fargo says. Here’s where to look
The pace of biotech deals is likely to pick up, but investors should think about smaller targets, said Wells Fargo analyst Mohit Bansal. Bansal called out both enticing valuations for small- and mid-cap biotech companies, which are now trading at an enterprise value of about one times cash, on average, and a tough regulatory environment […]
Read More
Searching for value in the battered biotech sector, which may not have hit bottom yet
Investors have been laser-focused on profit-producing companies, which has left companies in their pre-revenue stage on the sidelines. As a result, a growing number of biotech stocks are now trading below the value of the cash on their balance sheets. Over the past year, the SPDR S & P Biotech ETF is down nearly 44%, […]
Read More
Stocks making the biggest moves premarket: Turning Point Therapeutics, Lululemon, RH and others
Check out the companies making headlines before the bell: Turning Point Therapeutics (TPTX) – The biopharmaceutical company’s shares more than doubled in premarket trading after agreeing to be acquired by Bristol Myers Squibb (BMY) for $76 per share in cash, or $4.1 billion. Turning Point specializes in cancer treatments. Lululemon (LULU) – Lululemon shares rose […]
Read More
Find stability in this turbulent market – and a cash payout – with these stocks
Markets have logged wild swings in recent weeks and the new month kicked off Wednesday in similar fashion. But even in an unpredictable market, several companies are well-positioned to offer a good dividend payout and low volatility. Stocks are grappling with a murky start to the year as the Federal Reserve hikes rates and shrinks […]
Read More
When the market was tanking, these stocks were hitting all-time highs and could go even higher
While market losses were racking up, this group of stocks was breaking out to all-time highs and looks set for even more gains. The group is Big Pharma. It’s been long viewed as stodgy by investors looking for quicker price gains. Recently, however, as other stocks slid, these companies have become more attractive because of […]
Read More